MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$6.29
+0.27 (+4.49%)
Financial Highlights (FY 2026)
Revenue
851.65M
Net Income
-377,950,027
Gross Margin
69.9%
Profit Margin
-44.4%
Rev Growth
+6.7%
D/E Ratio
0.33
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | 31.6% | 31.6% |
| Operating Margin | -47.0% | -42.3% | -16.4% | -19.6% |
| Profit Margin | -44.4% | -42.2% | -21.1% | -16.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 851.65M | 798.03M | 74.53M | 73.26M |
| Gross Profit | 595.56M | 558.06M | 23.57M | 23.17M |
| Operating Income | -399,937,150 | -337,278,331 | -12,223,352 | -14,366,935 |
| Net Income | -377,950,027 | -318,735,967 | -15,758,896 | -11,828,489 |
| Gross Margin | 69.9% | 69.9% | 31.6% | 31.6% |
| Operating Margin | -47.0% | -42.3% | -16.4% | -19.6% |
| Profit Margin | -44.4% | -42.2% | -21.1% | -16.2% |
| Rev Growth | +6.7% | +6.7% | +5.3% | -4.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 73.92M | 73.92M | 122.72M | 106.53M |
| Total Equity | 226.90M | 226.90M | 215.66M | 214.57M |
| D/E Ratio | 0.33 | 0.33 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -344,482,215 | -306,651,147 | -16,042,014 | -17,865,875 |
| Free Cash Flow | — | — | -13,316,178 | -13,196,312 |